Search by Drug Name, NDC or Jcode
Internal Navigation
HCPCS Details
HCPC | J2327 |
Short Description | Inj risankizumab-rzaa 1 mg |
Long Description | Injection, risankizumab-rzaa, intravenous, 1 mg |
Pricing indicator | 51 |
Coverage code | C |
ASC payment group code | YY |
BETOS2 code | O1E |
Action code | N |
Type of service | 1 |
Effective date | 2023-01-01 |
Date Added | 2023-01-01 |
HCPCS/NDC Cross-Walk
NDC | HCPC | Description | Drug Name | Labeler Name | HCPCS Dosage | PKG Size | PKG QTY | Bill Units | Bill Units PKG |
---|---|---|---|---|---|---|---|---|---|
00074501501 | J2327 | Inj risankizumab-rzaa 1 mg | Skyrizi | AbbVie Inc. | 1 MG | 10 | 1 | 600 | 600 |
HCPCS Billing Calculator
Dosage given to patient (per dose) | |
---|---|
HCPCS Dosage | 1 MG |
HCPCS/CPT Billing Units | 1 |
Total doses ordered | |
Billing Units | 1 |
Drug Details
-
Risankizumab-rzaa injection is used to treat moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults whose psoriasis is too severe to be treated by topical medications alone. It is also used to treat active psoriatic arthritis (condition that causes joint pain and swelling and scales on the skin) in adults. Risankizumab-rzaa injection is also used to treat Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever) in adults. Risankizumab-rzaa is in a class of medications called monoclonal antibodies. It works by stopping the action of certain cells in the body that cause the symptoms of psoriasis.